New treatment for optic neuritis using a targeted small molecule inhibitor
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
This study is testing a new medication called TRE-515 to help people with optic neuritis, a condition that can cause vision problems, by targeting certain immune cells to reduce inflammation and improve vision.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trethera Corporation NIH-funded |
| Lab location | 1 site (Sherman Oaks, United States) |
| Project ID | NIH-11031427 on NIH RePORTER |
What this research studies
This research focuses on developing a new small molecule drug, TRE-515, aimed at treating optic neuritis, an autoimmune condition that can lead to vision loss. The approach involves inhibiting a specific enzyme, deoxycytidine kinase, which plays a crucial role in the activation of immune cells that contribute to the disease. By targeting these immune cells, the research aims to improve not only visual acuity but also other important visual functions that are often affected in patients. The study builds on promising preclinical findings that suggest TRE-515 can reduce inflammation and demyelination in the optic nerve.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with optic neuritis who are experiencing vision loss and have not fully recovered with standard steroid treatments.
Not a fit: Patients with optic neuritis who have already progressed to multiple sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved visual outcomes and quality of life for patients suffering from optic neuritis.
How similar studies have performed: Other research has shown success in targeting immune cell activation in similar autoimmune conditions, suggesting that this approach may be promising.
Where this research is happening
Sherman Oaks, United States
- Trethera Corporation — Sherman Oaks, United States (Active)
Researchers
- Principal investigator: Schultz, Kenneth — Trethera Corporation
- Study coordinator: Schultz, Kenneth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.